- Our Doctors
- Dr Isobel Porter
Dr Isobel Porter
Medical Oncologist, BBiomedSci, MBBS, FRACP
I am committed and passionate about offering high-quality and personalised patient care. I believe in prioritising communication, patient advocacy, and multidisciplinary collaboration to help achieve the best possible outcomes for patients
Languages spoken
English
Overview
Centres
Clinical interests
Clinical interests in Prostate Cancer, Colorectal Cancer, Kidney Cancer, Genitourinary Cancer, Gastrointestinal Cancer, Pancreatic Cancer, Bladder Cancer
Dr Isobel Porter is an Australian Medical Oncologist with a clinical interest in the management of patients with genitourinary and gastrointestinal cancers. Isobel completed her physician and specialist medical oncology training in several hospitals and cancer centres across Sydney’s North Shore before working as the Oncology Clinical Trials Fellow at Royal North Shore Hospital and then at GenesisCare, North Shore.
Isobel currently works as a specialist Medical Oncologist at Northern Beaches Hospital and at GenesisCare, Frenchs Forest.
Isobel is an active member of the local Urological and Gastrointestinal Cancers Multidisciplinary Teams (MDTs) as well as Healthscope’s National Oncology Safety Governance Group (OSGG). Isobel strongly believes in the role of clinical trials in helping improve access to innovative treatments for her patients.
Isobel also regularly attends meetings as part of the Geriatric Oncology Emerging Experts and Researchers (GOEER) Group, and liaises closely with GPs, Geriatricians, Palliative Care Physicians, and Allied Health practitioners with the aim to optimise outcomes particularly for patients with cancer over the age of 65 years.
Research interests
- Ageism and Oncogeriatrics
- Bisphosphonate therapy
- Prostate Cancer
Professional memberships
- Royal Australasian College of Physicians (RACP)
- Medical Oncology Group of Australia (MOGA)
- Geriatric Oncology Emerging Experts and Researchers (GOEER)
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
Publications
- Krasovitsky M, Porter I and Tuch G. ‘The Impact of Ageism in the Care of Older Adults with Cancer’, Current Opinion in Supportive & Palliative Care, March 2023;17(1):8-14. doi: 10.1097/SPC.0000000000000629.
- Porter I, Theodoulou E, et al. ‘Adoption of adjuvant bisphosphonates for early breast cancer into standard clinical practice: challenges and lessons learnt from comparison of the UK and Australian experience’, Journal of Bone Oncology, November 2021, 31:2212-1374, https://doi.org/10.1016/j.jbo.2021.100402
- Porter I, Guminski A, et al ‘A phase II, open-label study of durvalumab in combination with stereotactic body radiotherapy in androgen-intact patients with oligometastatic prostate cancer’, Poster presentation, ASCO Genitourinary Cancers Symposium, February 13- 15, 2020.
- Porter, I et al. ‘Adjuvant bone-modifying agents for women with early breast cancer: documenting Australian prescribing habits’, Oral and Poster presentation, MOGA ASM, Canberra, August 2019.
Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.